dc.contributor.author | Sahin, Ziver | |
dc.contributor.author | Bıcakcıgil, Muge | |
dc.contributor.author | Aksu, Kenan | |
dc.contributor.author | Kamali, Sevil | |
dc.contributor.author | Akar, Servet | |
dc.contributor.author | Onen, Fatos | |
dc.contributor.author | Karadag, Omer | |
dc.contributor.author | Ozbalkan, Zeynep | |
dc.contributor.author | Ates, Askin | |
dc.contributor.author | Ozer, Huseyin TE | |
dc.contributor.author | Yilmaz, Vuslat | |
dc.contributor.author | Seyahi, Emire | |
dc.contributor.author | Ozturk, Mehmet A | |
dc.contributor.author | Cefle, Ayse | |
dc.contributor.author | Cobankara, Veli | |
dc.contributor.author | Onat, A Mesut | |
dc.contributor.author | Tunc, Ercan | |
dc.contributor.author | Düzgün, Nursen | |
dc.contributor.author | Aydin, Sibel Z | |
dc.contributor.author | Yilmaz, Neslihan | |
dc.contributor.author | Fresko, İzzet | |
dc.contributor.author | Karaaslan, Yasar | |
dc.contributor.author | Kiraz, Sedat | |
dc.contributor.author | Akkoc, Nurullah | |
dc.contributor.author | Inanc, Murat | |
dc.contributor.author | Keser, Gokhan | |
dc.contributor.author | Uyar, F Aytul | |
dc.contributor.author | Direskeneli, Haner | |
dc.contributor.author | Saruhan-Direskeneli, Güher | |
dc.date.accessioned | 2019-12-19T07:02:46Z | |
dc.date.available | 2019-12-19T07:02:46Z | |
dc.date.issued | 2012 | |
dc.identifier.issn | 1478-6354 | |
dc.identifier.uri | https://doi.org/10.1186/ar3730 | |
dc.identifier.uri | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392822/ | |
dc.identifier.uri | http://hdl.handle.net/11655/20852 | |
dc.description.abstract | Introduction HLA-B*51 and HLA-B*52 are two close human leukocyte antigen (HLA) allele groups with minor amino acid differences. However, they are associated with two different vasculitides (HLA-B*51 in Behçet's disease and HLA-B*52 in Takayasu's arteritis (TAK)) and with major clinical and immunological differences. In this study, we aimed to screen a large cohort of TAK patients from Turkey for the presence of HLA-B*51 and HLA-B*52 as susceptibility and severity factors. Methods TAK patients (n = 330) followed at a total of 15 centers were included in the study. The mean age of the patients was 37.8 years, and 86% were women. DNA samples from the patients and healthy controls (HC; n = 210) were isolated, and the presence of HLA-B*51 or HLA-B*52 was screened for by using PCR with sequence-specific primers. Results We found a significant association of HLA-B*52 with TAK (20.9% vs HC = 6.7%, P = 0.000, OR = 3.7, 95% CI = 2.02 to 6.77). The distribution of HLA-B*51 did not differ between TAK patients and HCs (22.7% vs 24.8%, OR = 0.9, 95% CI = 0.60 to 1.34). The presence of HLA-B*52 decreased in late-onset patients (> 40 years of age; 12.0%, P = 0.024, OR = 0.43, 95% CI = 0.20 to 0.91). Patients with angiographic type I disease with limited aortic involvement also had a lower presence of HLA-B*52 compared to those with all other disease subtypes (13.1% vs 26%, P = 0.005, OR = 0.43, 95% CI = 0.23 to 0.78). Conclusions In this study, the previously reported association of TAK with HLA-B*52 in other populations was confirmed in patients from Turkey. The functional relevance of HLA-B*52 in TAK pathogenesis needs to be explored further. | |
dc.relation.isversionof | 10.1186/ar3730 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.title | Takayasu'S Arteritis is Associated with Hla-B*52, but not with Hla-B*51, in Turkey | |
dc.type | info:eu-repo/semantics/article | |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.relation.journal | Arthritis Research & Therapy | |
dc.contributor.department | Fizyoterapi ve Rehabilitasyon | |
dc.identifier.volume | 14 | |
dc.identifier.issue | 1 | |
dc.identifier.startpage | R27 | |
dc.description.index | PubMed | |
dc.description.index | WoS | |
dc.description.index | Scopus | |